OHSU Rare Disease Research Consortium Symposium 2015: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
| (12 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Template:OHSU Rare Disease Research Consortium Symposium 2015}} | {{Template:OHSU Rare Disease Research Consortium Symposium 2015}} | ||
==General Info== | ==General Info== | ||
[http://www.brownpapertickets.com/event/1319831 | [http://www.brownpapertickets.com/event/1319831 Register for the conference] | ||
== Schedule == | == Schedule == | ||
| Line 18: | Line 18: | ||
|-- | |-- | ||
| 4:00-5:00 | | 4:00-5:00 | ||
| [http://www.kathiresanlab.org/about-sek/ Sekar Kathiresan, M.D.] | | [http://www.kathiresanlab.org/about-sek/ Sekar Kathiresan, M.D.], Director of preventive cardiology, Mass General Hospital | ||
| Leveraging human knockouts to understand risk for and protection from disease | | Leveraging human knockouts to understand risk for and protection from disease | ||
|-- | |-- | ||
| Line 30: | Line 30: | ||
|-- | |-- | ||
| 6:20 to 6:30 | | 6:20 to 6:30 | ||
| Laura Hays, Ph.D., Executive Director, Fanconi Anemia Research Fund | | Laura Hays, Ph.D., Executive Director, [http://fanconi.org Fanconi Anemia Research Fund] | ||
| Making a difference: the David Frohnmayer advocacy formula | | Making a difference: the David Frohnmayer advocacy formula | ||
|-- | |-- | ||
| 6:30 to 6:35 | | 6:30 to 6:35 | ||
| Maureen Hoatlin | | [https://www.linkedin.com/in/hoatlin Maureen Hoatlin, Ph.D.,MBA], co-chair OHSU Rare Disease Research Consortium | ||
| OHSU Rare Disease Consortium overview and objective of the symposium | | OHSU Rare Disease Consortium overview and objective of the symposium | ||
|-- | |-- | ||
| 6:35 to 6:45 | | 6:35 to 6:45 | ||
| Eric Orwoll, M.D. | | [http://www.ohsu.edu/xd/research/research-expertise/researchers/?personid=586 Eric Orwoll, M.D.] | ||
| Osteogenesis imperfecta: a brittle bone disease with well- | | Osteogenesis imperfecta: a brittle bone disease with well-defined molecular pathologies but limited clinical insights and therapies | ||
|-- | |-- | ||
| 6:45 to 6:55 | | 6:45 to 6:55 | ||
| David Sprio, M.D. | | David Sprio, M.D., Co-founder and Chief Medical Officer, [http://reeldx.com ReelDx] | ||
| A novel | | A novel real patient video platform that enables patients and clinicians to share rare disease phenotypes | ||
|-- | |-- | ||
| 6:55 to 7:05 | | 6:55 to 7:05 | ||
| Evan Shereck, M.D. | | [http://www.ohsu.edu/xd/health/services/providers/index.cfm?personID=2057 Evan Shereck, M.D.] | ||
| Overview of the program in Pediatric Immunodeficiency Rare Disease Research Clinical Network | | Overview of the program in Pediatric Immunodeficiency Rare Disease Research Clinical Network | ||
|-- | |-- | ||
|7:05 to 7:10 | |7:05 to 7:10 | ||
| Markus Grompe, M.D. | | [http://www.ohsu.edu/xd/research/centers-institutes/stem-cell-center/faculty/markus-grompe.cfm Markus Grompe, M.D.] | ||
| Program in Fanconi anemia | | Program in Fanconi anemia | ||
|-- | |-- | ||
| 7:10 to 7:20 | | 7:10 to 7:20 | ||
| Cary | | [http://www.ohsu.edu/xd/education/schools/school-of-medicine/departments/basic-science-departments/molecular-and-medical-genetics/people/primary-faculty/cary-harding.cfm Cary Harding, M.D.] | ||
| Clinical Trials in inborn errrors of amino acid and fatty acid metabolism | | Clinical Trials in inborn errrors of amino acid and fatty acid metabolism | ||
|-- | |-- | ||
| 7:20 to 7:40 | | 7:20 to 7:40 | ||
| David Ellison, M.D. | | [http://www.ohsu.edu/xd/health/services/providers/?personid=201 David Ellison, M.D.] | ||
| | | | ||
:Part 1: All about that Bass: rare gene mutations and human blood pressure variation. | :Part 1: All about that Bass: rare gene mutations and human blood pressure variation. | ||
| Line 65: | Line 65: | ||
|-- | |-- | ||
| 7:40 to 8:20 | | 7:40 to 8:20 | ||
| Xiaobing Quan, M.D., Ph.D | | Xiaobing Quan, M.D., Ph.D, Executive Director, Translational Medicine at [http://www.regeneron.com Regeneron Pharmaceuticals, Inc.] | ||
| Accelerating opportunities from discovery to clinic in rare disease research | | Accelerating opportunities from discovery to clinic in rare disease research | ||
|-- | |-- | ||
|8:20 to 8:25 | |8:20 to 8:25 | ||
|Maureen Hoatlin | |[https://www.linkedin.com/in/hoatlin Maureen Hoatlin, Ph.D, MBA] | ||
|Final Remarks, Action items, organizing for the future | |Final Remarks, Action items, organizing for the future | ||
|-- | |-- | ||
Revision as of 21:33, 30 March 2015
|
April 7, 2015, from 4-8:30 pm at OHSU in the Joseph Vey Conference Center
General InfoSchedule
|
